Trials that use: Logistic regression
New to this method? Read the tutorial →
5,900 results
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- Lung Cancer Screening Eligibility Assessment: Complete Statistical AnalysisIndependent statistical analysis of Lung Cancer Screening Eligibility Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06133816).
- Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence…
- Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures: Complete Statistical AnalysisIndependent statistical analysis of LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780268).
- Lyophilized IMVAMUNE® (1×10^8 TCID50) Versus Liquid IMVAMUNE® (1×10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2×10^7 TCID50) Administered Intradermally: Complete Statistical AnalysisIndependent statistical analysis of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally: primary endpoint results, effect estimate with confidence…
- M-MILKIndependent statistical analysis of Multisensory Early Oral Administration of Human Milk in Preterm Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06230848).
- M-RePoRTIndependent statistical analysis of Metformin for Rising PSA Remote Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02376166).
- M032-HSV-1Independent statistical analysis of Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- M2-ABMGIndependent statistical analysis of A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- M3541 in Combination With Radiotherapy in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of M3541 in Combination With Radiotherapy in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03225105).
- MA181Independent statistical analysis of Assessing Choice in the Employer Setting (ACES) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00808808).
- MACH19Independent statistical analysis of RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- MACS0911Independent statistical analysis of Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- MADIndependent statistical analysis of Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00487552).
- MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- MAGE-A4ᶜ¹º³²T for Multi-Tumor: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A4ᶜ¹º³²T for Multi-Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03132922).
- MAGELLAN-3Independent statistical analysis of Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in…
- Magnesium vs Placebo for Tonsillectomy: Complete Statistical AnalysisIndependent statistical analysis of Magnesium vs Placebo for Tonsillectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02218424).
- MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): Complete Statistical AnalysisIndependent statistical analysis of MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study: Complete Statistical AnalysisIndependent statistical analysis of Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01706705).
- Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent: Complete Statistical AnalysisIndependent statistical analysis of Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent: primary endpoint results, effect estimate…
- Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression: Complete Statistical AnalysisIndependent statistical analysis of Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01051440).
- Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- MAGNITUDEIndependent statistical analysis of Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Maintaining Nonsmoking: Older Smokers – 1: Complete Statistical AnalysisIndependent statistical analysis of Maintaining Nonsmoking: Older Smokers - 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00086385).
- MALMSIndependent statistical analysis of Metformin to Augment Low Milk Supply (MALMS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02179788).
- Management of Chronic Pain and PTSD in Gulf War Veterans With tDCS+Prolonged Exposure: Complete Statistical AnalysisIndependent statistical analysis of Management of Chronic Pain and PTSD in Gulf War Veterans With tDCS+Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Management of Distal Radius Fractures in Children Younger Than 11 Years Old.: Complete Statistical AnalysisIndependent statistical analysis of Management of Distal Radius Fractures in Children Younger Than 11 Years Old.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Management of Etonogestrel Subdermal Implant-related Bleeding: Complete Statistical AnalysisIndependent statistical analysis of Management of Etonogestrel Subdermal Implant-related Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01658995).
- Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia: Complete Statistical AnalysisIndependent statistical analysis of Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage: Complete Statistical AnalysisIndependent statistical analysis of Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- MANDALAA detailed statistical analysis of the phase 3 MANDALA trial of budesonide/albuterol metered-dose inhalers versus albuterol in adults and children 4 years of age or older with asthma, including time-to-event, rate, binary,…
- MANTAIndependent statistical analysis of Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease: primary endpoint results, effect estimate with confidence interval, sample-size…
- MAP-PAFIndependent statistical analysis of Ablation of the Pulmonary Veins for Paroxysmal Afib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00744874).
- MAP-XIndependent statistical analysis of Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- MAPSIndependent statistical analysis of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01411345).
- Maraviroc as GVHD Prophylaxis in Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Maraviroc as GVHD Prophylaxis in Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02167451).
- Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00948753).
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- MARRSIndependent statistical analysis of Millipede AspiRation for Revascularization in Stroke (MARRS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05714501).
- MARSIndependent statistical analysis of Microvascular Flow Assessment Repeatability Study: The MARS Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01242020).
- MARSIndependent statistical analysis of Project MARS: Mobile-Assistance for Regulating Smoking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04376489).
- MARS GIIndependent statistical analysis of Safety and Feasibility of the Use of the Dual Robotic Arm Accessory With the Levita Magnetic Surgical System in Laparoscopic Procedures: primary endpoint results, effect estimate with confidence…
- MASCIIndependent statistical analysis of Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…